Massachusetts-based AI drug discovery company Vesalius Therapeutics emerged from stealth with an investment of USD 75 million from its founder Flagship Pioneering.
The proceeds will be used to fuel the company’s preclinical development efforts with plans to advance multiple programs within the next two years as well as test its platform across various areas including neurological and cardiovascular diseases. The company will also grow its employee base by 200 with focus on the data and computational areas and pursue partnerships with other drug developers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.